The risk of ineffective MDR/XDR TB treatment, based on bedaquilin: factors and their influence

S. Borisov (Moscow, Russian Federation), A. Filippov (Moscow, Russian Federation), D. Ivanova (Moscow, Russian Federation), T. Ivanushkina (Moscow, Russian Federation), E. Belilovsky (Moscow, Russian Federation)

Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Session: Multidrug-resistant tuberculosis
Session type: E-poster session
Number: 461
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Borisov (Moscow, Russian Federation), A. Filippov (Moscow, Russian Federation), D. Ivanova (Moscow, Russian Federation), T. Ivanushkina (Moscow, Russian Federation), E. Belilovsky (Moscow, Russian Federation). The risk of ineffective MDR/XDR TB treatment, based on bedaquilin: factors and their influence. 461

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016



TB failures, risk factors and therapeutical results
Source: Eur Respir J 2003; 22: Suppl. 45, 523s
Year: 2003

Attempt to estimate risk factors for drug resistance (DR) in tuberculosis
Source: Eur Respir J 2005; 26: Suppl. 49, 653s
Year: 2005

The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis
Source: Eur Respir J 2012; 39: 626-634
Year: 2012



The problem of multi-drug resistant (MDR)-TB
Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties
Year: 2005


The influence of the epidemic risk factor on advanced processes in adolescents with newly-detected pulmonary TB
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007


Could side effects of MDR-TB treatment change the outcome of the disease?
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015


The assessment of risk factors and treatment of pulmonary TB relapses
Source: Eur Respir J 2006; 28: Suppl. 50, 129s
Year: 2006

Risk factors in tuberculosis and its influence on chemotherapy efficiency
Source: Eur Respir J 2005; 26: Suppl. 49, 649s
Year: 2005

Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country.
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020


Outcome of multidrug resistant tuberculosis (MDR-TB) treatment with possible influencing factors
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011


HIV and multidrug-resistant tuberculosis: overlapping risk factors
Source: Eur Respir J 2015; 45: 567-569
Year: 2015


Patient choice promotes adherence in preventive treatment for latent tuberculosis
Source: Eur Respir J 2007; 30: 728-735
Year: 2007



Antituberculosis drug-induced hepatotoxicity: influence on the management and outcome of active tuberculosis (TB)
Source: Annual Congress 2007 - Epidemiology of tuberculosis II
Year: 2007


Effect of the risk factors on the characteristics of the disease in patients with pulmonary tuberculosis
Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups
Year: 2008

Factors affecting outcomes of individualised treatment for drug resistant tuberculosis in an endemic region>
Source: International Congress 2017 – TB: co-morbidities and outcome
Year: 2017

Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007


Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015


Smoking is a risk factor for TB infection, but is it an additional mortality risk?
Source: Annual Congress 2011 - Management of tuberculosis
Year: 2011

The effect, the consequences and associated factors of poverty on tuberculosis in Turkey
Source: Eur Respir J 2003; 22: Suppl. 45, 517s
Year: 2003